Taro Provides Results for September 30, 2023

Rhea-AI Summary

Taro Pharmaceutical Industries Ltd. reports unaudited financial results for Q3 and six months ended September 30, 2023. Net sales increased due to a one-time GTN adjustment. Gross profit also increased. R&D expenses and SMG&A expenses increased. Operating income improved. Net income turned positive. Cash flow from operations improved. Cash and cash equivalents increased.

Positive

• Net sales increased due to a one-time GTN adjustment. Gross profit improved. Operating income turned positive. Net income improved. Cash flow from operations improved. Cash and cash equivalents increased.

Negative

• None.

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.

Quarter ended September 30, 2023 Highlights ─ compared to September 30, 2022

• Net sales of $148.2 million increased, in part, due to a one-time gross-to-net (“GTN”) adjustment. Excluding the impact of the one-time GTN adjustments in both quarters, the sales growth was mid-single-digits.
• Gross profit of $73.6 million (49.7% of net sales) compared to $47.0 million (36.0% of net sales).
• Research and development (R&D) expenses of $14.3 million increased $2.8 million, principally the result of increased clinical studies.
• Selling, marketing, general and administrative expenses (SMG&A) of $54.5 million included certain one-time charges of $6.1 million principally related to work performed by the Special Committee that was established by the Taro Board to consider the proposal submitted by Sun Pharmaceutical Industries Ltd. on May 26, 2023. Excluding these charges, SMG&A was $48.4 million compared to $42.3 million.
• Operating income was $4.7 million; excluding the impact from the certain one-time charges, operating income was $10.9 million compared to operating loss of $(6.8) million in the previous year quarter.
• Interest and other financial income of $14.0 million increased $9.7 million.
• Tax expense of $9.1 million compared to a tax benefit of $2.1 million in the prior year quarter.
• Net income was $8.5 million compared to net loss of $(2.8) million, resulting in earnings per share of $0.23 compared to loss per share of $(0.07). Excluding the impact of the aforementioned certain one-time charges, net income was $14.3 million, resulting in earnings per share of $0.38.

Six Months ended September 30, 2023 Highlights ─ compared to September 30, 2022

• Net sales of $307.1 million increased $19.9 million, or 6.9%.
• Gross profit of $137.7 million (44.8% of net sales in each period) increased $9.1 million.
• R&D expenses of $30.5 million increased $7.4 million, principally the result of increased clinical studies.
• SMG&A of $110.4 million included certain one-time charges of $12.3 million (of which $6.2 million from the first quarter of the current year) related to the aforementioned certain one-time charges. Excluding these charges, SMG&A was $98.1 million, in line with the prior year quarter.
• Operating loss was $(3.2) million; excluding the impact from the certain one-time charges, operating income was $9.1 million compared to $7.2 million.
• Interest and other financial income of $24.9 million increased from $6.2 million.
• Net income was $18.6 million compared to $11.3 million, resulting in earnings per share of $0.49 compared to earnings per share of $0.30. Excluding the impact of the aforementioned certain one-time charges, net income was $29.2 million, resulting in earnings per share of $0.78.

Cash Flow and Balance Sheet Highlights

• Net cash provided by operations for the six months ended September 30, 2023 was $55.3 million compared to net cash used in operations of $37.7 million for the six months ended September 30, 2022.
• As of September 30, 2023, cash and cash equivalents, short-term bank deposits and marketable securities (both short- and long-term) increased $40.2 million to $1.3 billion from March 31, 2023.

The Company cautions that the foregoing 2023 financial information is unaudited and is subject to change.

************************

About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

SAFE HARBOR STATEMENT
The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2024. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

**Financial Tables Follow**

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(U.S. dollars in thousands, except share data)
	Quarter Ended								Six Months Ended
	September 30,								September 30,
		2023				2022				2023				2022
Sales, net	$	148,202			$	130,498			$	307,096			$	287,163
Cost of sales		74,600				83,536				169,410				158,595
Gross profit		73,602				46,962				137,686				128,568
Operating Expenses:
Research and development		14,325				11,522				30,470				23,030
Selling, marketing, general and administrative		54,537				42,255				110,398				98,377
Operating income/(loss) *		4,740				(6,815	)			(3,182	)			7,161
Financial (income)/expense, net:
Interest and other financial income		(13,972	)			(4,296	)			(24,862	)			(6,222	)
Foreign exchange (income)/expense		1,623				2,788				(460	)			3,082
Other gain, net		566				395				956				839
Income/(loss) before income taxes		17,655				(4,913	)			23,096				11,140
Tax expense/(benefit)		9,108				(2,100	)			4,515				(126	)
Net income/(loss) *	$	8,547			$	(2,813	)		$	18,581			$	11,266
Net income/(loss) per ordinary share:
Basic and Diluted *	$	0.23			$	(0.07	)		$	0.49			$	0.30
Weighted-average number of shares used to compute net income/(loss) per share:
Basic and Diluted		37,584,891				37,584,891				37,584,891				37,584,891
May not foot due to rounding.

* For the quarter ended September 30, 2023, excluding the impact from the certain one-time charges of $6.1 million (see page one of release for a description), operating income was $10.9 million compared to operating loss of $(6.8) million. Excluding the impact of the certain one-time charges, net income was $14.3 million, resulting in earnings per share of $0.38.

* For the six months ended September 30, 2023, excluding the impact from the certain one-time charges of $12.3 million (see page one of release for a description), operating income was $9.1 million compared to $7.2 million. Excluding the impact of the certain one-time charges, net income was $29.2 million, resulting in earnings per share of $0.78.

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
		September 30,			March 31,
		2023			2023
ASSETS		(unaudited)			(audited)
CURRENT ASSETS:
Cash and cash equivalents		$	269,011		$	154,495
Short-term bank deposits			119,980			119,980
Marketable securities			518,058			575,814
Accounts receivable and other:
Trade, net			181,064			202,260
Other receivables and prepaid expenses			46,254			57,210
Inventories			208,188			226,669
TOTAL CURRENT ASSETS			1,342,555			1,336,428
Marketable securities			388,370			404,896
Property, plant and equipment, net			189,893			190,139
Deferred income taxes			100,807			103,672
Goodwill			17,231			17,231
Other assets			80,617			83,147
TOTAL ASSETS		$	2,119,473		$	2,135,513
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables		$	43,059		$	68,485
Other current liabilities			318,429			317,064
TOTAL CURRENT LIABILITIES			361,488			385,549
Deferred taxes and other long-term liabilities			10,429			19,106
TOTAL LIABILITIES			371,917			404,655
Taro shareholders' equity			1,747,556			1,730,858
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		$	2,119,473		$	2,135,513

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(U.S. dollars in thousands)
		Six Months Ended September 30,
			2023				2022
Cash flows from operating activities:
Net income		$	18,581			$	11,266
Adjustments required to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization			15,498				13,994
Change in derivative instruments, net			—				(24	)
Decrease in goodwill and intangible assets			250				—
Effect of change in exchange rate on marketable securities and bank deposits			202				1,358
Deferred income taxes, net			2,539				2,245
Decrease (increase) in trade receivables, net			20,927				(2,071	)
Decrease (increase) in inventories, net			18,356				(5,316	)
Decrease in other receivables, income tax receivables, prepaid expenses and other			10,862				5,739
Decrease in trade, income tax, accrued expenses and other payables			(28,837	)			(71,798	)
(Income)/expense from amortization of marketable securities bonds, net			(3,085	)			6,940
Net cash provided by (used in) operating activities			55,293				(37,667	)
Cash flows from investing activities:
Purchase of plant, property & equipment, net			(13,800	)			(3,443	)
Investment in other intangible assets			(50	)			(68	)
Investment in short-term bank deposits, net			—				(48,044	)
Proceeds from marketable securities, net			73,716				15,516
Net cash used in (provided by) investing activities			59,866				(36,039	)
Cash flows from financing activities:
Net cash used in financing activities			—				—
Effect of exchange rate changes on cash and cash equivalents			(643	)			(2,237	)
Increase (decrease) in cash and cash equivalents			114,516				(75,943	)
Cash and cash equivalents at beginning of period			154,495				251,134
Cash and cash equivalents at end of period		$	269,011			$	175,191
Cash Paid during the year for:
Income taxes		$	6,232			$	3,091
Cash Received during the year for:
Income taxes		$	12,930			$	14,156
Non-cash investing transactions:
Purchase of property, plant and equipment included in accounts payable		$	1,097			$	3,206
Non-cash financing transactions:
Purchase of marketable securities, net		$	157			$	6,199
Sale of marketable securities		$	157			$	—

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026372692/en/

William J. Coote

VP, CFO

(914) 345-9001

William.Coote@taro.com

 

Source: Taro Pharmaceutical Industries Ltd.

FAQ

What were Taro Pharmaceutical's net sales for the quarter ended September 30, 2023?

Taro Pharmaceutical's net sales for the quarter ended September 30, 2023 were $148.2 million.

What were Taro Pharmaceutical's gross profit for the quarter ended September 30, 2023?

Taro Pharmaceutical's gross profit for the quarter ended September 30, 2023 was $73.6 million.

What were Taro Pharmaceutical's R&D expenses for the quarter ended September 30, 2023?

Taro Pharmaceutical's R&D expenses for the quarter ended September 30, 2023 were $14.3 million.

What were Taro Pharmaceutical's SMG&A expenses for the quarter ended September 30, 2023?

Taro Pharmaceutical's SMG&A expenses for the quarter ended September 30, 2023 were $54.5 million.

What was Taro Pharmaceutical's operating income for the quarter ended September 30, 2023?

Taro Pharmaceutical's operating income for the quarter ended September 30, 2023 was $4.7 million.

What was Taro Pharmaceutical's net income for the quarter ended September 30, 2023?

Taro Pharmaceutical's net income for the quarter ended September 30, 2023 was $8.5 million.

What was Taro Pharmaceutical's cash flow from operations for the six months ended September 30, 2023?

Taro Pharmaceutical's cash flow from operations for the six months ended September 30, 2023 was $55.3 million.

What was Taro Pharmaceutical's cash and cash equivalents as of September 30, 2023?

Taro Pharmaceutical's cash and cash equivalents as of September 30, 2023 were $1.3 billion.